| Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study 2021 · chondroitin sulfate only · Adults aged 45–75 with symptomatic knee osteoarthritis | 800 mg | 2 years | — |
| Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA 1998 · CS 4&6 group · Patients with osteoarthritis of the finger joints | 400 mg | 3 years | — |
| Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study 2021 · glucosamine sulfate and chondroitin sulfate (double active) · Adults aged 45–75 with symptomatic knee osteoarthritis | 800 mg | 2 years | — |
| Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial 2009 · chondroitin 4 and 6 sulfate group · Patients with knee osteoarthritis | 800 mg | 2 years | 309 |
| Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT) 2017 · Group CS · Adults older than 50 with symptomatic primary knee osteoarthritis | 800 mg | 26 weeks | 199 |
| Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee 2010 · chondroitin sulfate · Patients with femorotibial knee osteoarthritis; age and sex not specified | 1.2 g | 26 weeks | 178 |
| Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial 2005 · CS · Patients with knee osteoarthritis | 800 mg | 2 years | 150 |
| Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center 2011 · CS group · Patients with symptomatic hand osteoarthritis and radiographic evidence of hand OA | 800 mg | 26 weeks | 80 |
| Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study 2001 · CS group · Patients with femorotibial osteoarthritis of the knee; age and sex not reported | 1 g | 90 days | 63 |
| Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo 1998 · CS 3 x 400 mg/day capsules · Patients with mono- or bilateral knee osteoarthritis, Kellgren and Lawrence radiographic grade I to III | 1.2 g | 90 days | 43 |
| Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo 1998 · CS 1200 mg/day oral gel · Patients with mono- or bilateral knee osteoarthritis, Kellgren and Lawrence radiographic grade I to III | 1.2 g | 90 days | 40 |
| Effectiveness of Non-Animal Chondroitin Sulfate Supplementation in the Treatment of Moderate Knee Osteoarthritis in a Group of Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2019 · experimental group (non-animal CS) · Men and women aged 55 years and over with overweight (BMI 25–30 kg/m²) and moderate knee osteoarthritis or related mobility impairment and joint discomfort | 600 mg | 12 weeks | 30 |
| Bifidobacterium animalis subsp. lactis Probio-M8 enhances chondroitin efficacy for knee osteoarthritis in postmenopausal women via the gut-joint axis 2025 · placebo group · Postmenopausal women aged 50–70 with clinically diagnosed knee osteoarthritis | 900 mg | 90 days | 30 |
| Effects of chondroitin sulfate on brain response to painful stimulation in knee osteoarthritis patients. A randomized, double-blind, placebo-controlled functional magnetic resonance imaging study 2017 · CS group · Patients with knee osteoarthritis; age and sex not stated | 800 mg | 120 days | 22 |
| Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo 2004 · chondroitin sulfate (CS) group · patients with symptomatic knee osteoarthritis | 800 mg | 180 days | — |
| Potential effects of chondroitin sulfate on joint swelling: a GAIT report 2008 · chondroitin sulfate · Adults with symptomatic, radiographic knee osteoarthritis | 1.2 g | 24 weeks | — |
| Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study 2010 · CS · Patients with symptomatic knee osteoarthritis and concomitant psoriasis | 800 mg | 90 days | — |
| Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study 2013 · CS 1200 · Men and women over 45 years with knee osteoarthritis | 1.2 g | 90 days | — |
| Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study 2013 · CS 3*400 · Men and women over 45 years with knee osteoarthritis | 1.2 g | 90 days | — |
| Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan 2018 · low-dose group (control group) · Patients with painful, Kellgren-Lawrence grade 2–3 knee osteoarthritis | 260 mg | 1 year | — |
| Efficacy of Chondroitin Sulfate for Painful Knee Osteoarthritis: A One-Year, Randomized, Double-Blind, Multicenter Clinical Study in Japan 2018 · high-dose group · Patients with painful, Kellgren-Lawrence grade 2–3 knee osteoarthritis | 1.56 g | 1 year | — |
| Cost-Effectiveness Analysis of Pharmaceutical-Grade Chondroitin Sulfate for Knee Osteoarthritis Based on Individual Patient Data from a Randomized Clinical Trial 2025 · chondroitin sulfate group · Adults over 50 years old with primary knee osteoarthritis and knee pain for at least 3 months | 800 mg | 26 weeks | — |
| Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis 1996 · CS group · Patients with knee osteoarthritis | 1.2 g | 90 days | — |
| Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis 1998 · chondroitin sulfate group · Patients with idiopathic or clinically symptomatic knee osteoarthritis, Kellgren and Lawrence radiological scores I–III; age and sex not reported | 800 mg | 26 weeks | — |
| Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study 1998 · chondroitin sulfate group · Adults aged 35–78 years, both sexes, with symptomatic knee osteoarthritis | 800 mg | 1 year | — |
| [Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6)] 1998 · CS 4&6 · Patients with femorotibial osteoarthritis of the knee | 800 mg | 1 year | — |
| Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis 2015 · GIII · Adults with radiographic knee osteoarthritis, Kellgren/Lawrence grade 2–3; age and sex not specified | 1.2 g | 16 weeks | 306 |
| Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis 2015 · GI · Adults with radiographic knee osteoarthritis, Kellgren/Lawrence grade 2–3; age and sex not specified | 1.2 g | 16 weeks | 302 |
| Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study 2016 · GC group · Men and women aged 40–75 with moderate-to-severe knee osteoarthritis | 1.2 g | 180 days | 66 |
| Effectiveness of Cucumis sativus extract versus glucosamine-chondroitin in the management of moderate osteoarthritis: a randomized controlled trial 2018 · GC Group · Males and females aged 40–75 years with mild to moderate knee osteoarthritis | 600 mg | 180 days | 61 |
| Effects of N-acetyl glucosamine and chondroitin sulfate supplementation on knee pain and self-reported knee function in middle-aged and older Japanese adults: a randomized, double-blind, placebo-controlled trial 2016 · Glu/Cho group · Japanese adults aged 52–87 with knee pain and/or stiffness | 180 mg | 24 weeks | 50 |
| Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial 2017 · GCM · Patients with Kellgren-Lawrence grade I-II knee osteoarthritis; age and sex not specified | 1.2 g | 90 days | 50 |
| Comparison of Glucosamine-Chondroitin Sulfate with and without Methylsulfonylmethane in Grade I-II Knee Osteoarthritis: A Double Blind Randomized Controlled Trial 2017 · GC · Patients with Kellgren-Lawrence grade I-II knee osteoarthritis; age and sex not specified | 1.2 g | 90 days | 49 |
| Bifidobacterium animalis subsp. lactis Probio-M8 enhances chondroitin efficacy for knee osteoarthritis in postmenopausal women via the gut-joint axis 2025 · probiotic group · Postmenopausal women aged 50–70 with clinically diagnosed knee osteoarthritis | 900 mg | 90 days | 38 |
| [A comparative analysis of intravesical sodium hyaluronate monotherapy and its combination with oral chondroitin sulfate in patietns with bladder pain syndrome/intersticial cystitis] 2019 · Group 2 · Patients with bladder pain syndrome/interstitial cystitis; sex and age range not specified | 1.17 g | 12 weeks | 29 |
| Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial 2009 · Glucosamine HCl plus chondroitin sulfate group (G+C) · Adults with moderate to severe osteoarthritis of the knee; age and sex distribution not specified for this arm. | 600 mg | 90 days | 26 |
| The effect of oral low molecular weight liquid hyaluronic acid combination with glucosamine and chondroitin on knee osteoarthritis patients with mild knee pain: An 8-week randomized double-blind placebo-controlled trial 2021 · A+HA group · Men and women aged 40 years or older with knee osteoarthritis and mild knee pain | 250 mg | 8 weeks | 24 |
| A randomized double-blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study 2001 · active medication group · People diagnosed with capsulitis, disk displacement, disk dislocation, or painful osteoarthritis of the temporomandibular joint | 1.2 g | 12 weeks | 14 |
| Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis 2000 · intervention group · Adults with knee osteoarthritis; age and sex not reported | 1.6 g | 26 weeks | — |
| Potential effects of chondroitin sulfate on joint swelling: a GAIT report 2008 · glucosamine plus chondroitin sulfate · Adults with symptomatic, radiographic knee osteoarthritis | 1.2 g | 24 weeks | — |
| Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled study 2012 · GCQ supplement · Japanese subjects with symptomatic knee osteoarthritis | 60 mg | 16 weeks | — |
| Novel Hydrolyzed Chicken Sternal Cartilage Extract Improves Facial Epidermis and Connective Tissue in Healthy Adult Females: A Randomized, Double-Blind, Placebo-Controlled Trial 2019 · intervention · Females aged 39–59 years described as healthy adults | 200 mg | 12 weeks | — |
| Curcumagalactomannoside/Glucosamine Combination Improved Joint Health Among Osteoarthritic Subjects as Compared to Chondroitin Sulfate/Glucosamine: Double-Blinded, Randomized Controlled Study 2020 · Group II (CHN-GLN) · Adults with confirmed class I–III osteoarthritis; ages not reported; 38 males and 42 females across both groups | 830 mg | 12 weeks | — |
| Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial 2021 · GS/CS group · Patients with knee osteoarthritis, Kellgren-Lawrence grades 2 or 3, with a mean WOMAC pain subscale score of at least 40 mm | 1.2 g | 24 weeks | — |
| Glucosamine-containing supplement improves locomotor functions in subjects with knee pain: a randomized, double-blind, placebo-controlled study 2015 · GCQID group · Japanese women and men aged 40–74 years with knee pain | 60 mg | 16 weeks | 50 |
| Effects of cartilage-supporting nutritional supplementation on knee osteoarthritis symptoms and quality of life in a 12-week randomized double-blind placebo-controlled pilot study 2025 · Verum · Adults with mild-to-moderate knee osteoarthritis and slight-to-moderate knee pain; mean age 62.7 years; women and men | 200 mg | 12 weeks | 36 |
| Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study 2020 · treatment group · Adults with knee osteoarthritis and a swollen joint | 240 mg | 4 weeks | 15 |
| Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study 1999 · combination therapy · male U.S. Navy diving and special warfare personnel with chronic pain and radiographic degenerative joint disease of the knee or low back | 1.2 g | 16 weeks | — |
| Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers 2019 · Nonanimal chondroitin sulfate · Healthy male volunteers | 2.4 g | 1 day | — |
| Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers 2019 · Animal-derived chondroitin sulfate · Healthy male volunteers | 2.4 g | 1 day | — |
| Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens 2015 · chondroitin sulfate · Adults aged 45–75 with chronic knee pain and medial tibio-femoral compartment narrowing consistent with symptomatic knee osteoarthritis | 800 mg | 2 years | 151 |
| Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study 2016 · Chondroitin sulfate · Men and women aged 40 years or older with primary symptomatic knee osteoarthritis and clinical synovitis | 400 mg | 543 days | 97 |
| Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study 2017 · chondroitin sulfate · Adults with symptomatic knee osteoarthritis and clinical synovitis; age and sex range not specified | 1.2 g | 2 years | 97 |
| Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI 2011 · CS group · Adults aged 40–80 years, both sexes, with primary knee osteoarthritis and clinical signs of synovitis | 800 mg | 1 year | 35 |
| Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI 2011 · Placebo group followed by CS · Adults aged 40–80 years, both sexes, with primary knee osteoarthritis and clinical signs of synovitis | 800 mg | 26 weeks | 34 |
| Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens 2015 · glucosamine-chondroitin combination · Adults aged 45–75 with chronic knee pain and medial tibio-femoral compartment narrowing consistent with symptomatic knee osteoarthritis | 800 mg | 2 years | 151 |
| Differences in Serum Biomarkers Between Combined Glucosamine and Chondroitin Versus Celecoxib in a Randomized, Double-blind Trial in Osteoarthritis Patients 2020 · Combined glucosamine hydrochloride plus chondroitin sulfate (GH+CS) · Patients with knee osteoarthritis; age and sex not specified | 1.2 g | 26 weeks | 96 |
| Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans 2015 · Glucosamine and chondroitin (G&C) intervention · Healthy, overweight, non-smoking men and women aged 20–55 years | 1.2 g | 4 weeks | 18 |
| Effects of glucosamine-chondroitin combination on synovial fluid IL-1β, IL-6, TNF-α and PGE2 levels in internal derangements of temporomandibular joint 2015 · study group · Women aged 18–40 with internal derangement of the temporomandibular joint, pain lasting longer than 4 weeks, and limitation in mouth opening | 1.2 g | 8 weeks | — |
| Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial 2021 · GLN-CHN combination group · Adults with knee osteoarthritis | 830 mg | 6 weeks | — |